Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 04 2023
Historique:
received: 07 10 2022
accepted: 02 04 2023
medline: 14 4 2023
entrez: 12 4 2023
pubmed: 13 4 2023
Statut: epublish

Résumé

Macular peeling combined or followed by intravitreal dexamethasone implant (DEX-i) was recommended as an efficacy approach for tractional diabetic macular edema (tDME). Knowing the synergistic effect of cataract surgery and DEX-i one month earlier in eyes with DME, we compared Epiretinal Membrane/Inner Limiting Membrane (ERM/ILM) peeling preceded by DEX-i one month before versus ERM/ILM peeling alone for the treatment of tDME. A retrospective study on patients affected by tDME who underwent ERM/ILM peeling one month after DEX-i (n = 11; Group A) or ERM/ILM peeling alone (n = 10; Group B) was performed. Longitudinal comparison of best-correct visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) between the time of surgery (T

Identifiants

pubmed: 37045880
doi: 10.1038/s41598-023-32780-5
pii: 10.1038/s41598-023-32780-5
pmc: PMC10097727
doi:

Substances chimiques

Dexamethasone 7S5I7G3JQL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5990

Informations de copyright

© 2023. The Author(s).

Références

Jpn J Ophthalmol. 2012 May;56(3):280-7
pubmed: 22438196
Ophthalmol Sci. 2022 Aug 09;2(4):100207
pubmed: 36385773
Br J Ophthalmol. 2020 Jan;104(1):39-46
pubmed: 31040132
Drug Des Devel Ther. 2019 Dec 03;13:4107-4114
pubmed: 31819377
Taiwan J Ophthalmol. 2019 Dec 13;9(4):224-232
pubmed: 31942427
Acta Ophthalmol Scand. 2001 Oct;79(5):435-40
pubmed: 11594975
Front Pharmacol. 2021 Apr 15;12:635101
pubmed: 33935724
Ophthalmology. 1998 Oct;105(10):1801-15
pubmed: 9787347
Sci Rep. 2021 Apr 7;11(1):7665
pubmed: 33828222
Retina. 2010 Oct;30(9):1488-95
pubmed: 20924264
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4605-9
pubmed: 21421864
Retina. 2017 Oct;37(10):1813-1819
pubmed: 28207608
Retina. 2015 May;35(5):921-8
pubmed: 25545486
Clin Ophthalmol. 2013;7:549-53
pubmed: 23620653
J Diabetes Res. 2019 Dec 20;2019:8164250
pubmed: 31930145
Pharmaceutics. 2020 Jul 26;12(8):
pubmed: 32722556
Drug Des Devel Ther. 2017 Aug 16;11:2359-2372
pubmed: 28860707
Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1415-20
pubmed: 22354371
Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32
pubmed: 19171208
Clin Ophthalmol. 2021 Jul 30;15:3221-3230
pubmed: 34354341
Ophthalmology. 2010 Jun;117(6):1087-1093.e3
pubmed: 20299105
Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):80-6
pubmed: 20702826
Graefes Arch Clin Exp Ophthalmol. 2002 Jun;240(6):423-9
pubmed: 12107507
Retina. 2015 Sep;35(9):1719-25
pubmed: 26079478
Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):20-5
pubmed: 15290152
Retina. 2022 Aug 1;42(8):1455-1464
pubmed: 35395660
Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1165-1172
pubmed: 32152718
Ther Adv Chronic Dis. 2015 Sep;6(5):234-45
pubmed: 26336592
Am J Ophthalmol. 2007 Dec;144(6):878-885
pubmed: 17936715
Retina. 2014 Mar;34(3):490-6
pubmed: 23903795
Acta Ophthalmol. 2021 Feb;99(1):e74-e80
pubmed: 32588978
Retina. 2011 May;31(5):915-23
pubmed: 21487341
Retina. 2016 Jun;36(6):1143-52
pubmed: 26871523
Indian J Ophthalmol. 2021 Nov;69(11):3297-3301
pubmed: 34708792
Br J Ophthalmol. 2006 Jan;90(1):33-6
pubmed: 16361663
Korean J Ophthalmol. 2019 Jun;33(3):249-258
pubmed: 31179656
Sci Rep. 2020 Mar 26;10(1):5534
pubmed: 32218471
Br J Ophthalmol. 2015 Aug;99(8):1078-81
pubmed: 25680616
Eye (Lond). 2010 Oct;24(10):1545-53
pubmed: 20523361
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Mediators Inflamm. 2012;2012:872978
pubmed: 23028204
Retina. 2005 Oct-Nov;25(7):883-8
pubmed: 16205568
Ophthalmologica. 2017;237(4):185-222
pubmed: 28423385
Ophthalmologica. 2015;233(3-4):169-75
pubmed: 25924737
Surv Ophthalmol. 1984 May;28 Suppl:493-8
pubmed: 6379948
J Ophthalmol. 2018 May 07;2018:9246384
pubmed: 29854429
Curr Eye Res. 2013 Dec;38(12):1261-5
pubmed: 23972000
Ophthalmologica. 2016;235(3):150-6
pubmed: 26908130
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):1-8
pubmed: 30377798
Am J Ophthalmol Case Rep. 2022 Feb 17;26:101401
pubmed: 35243151
Invest Ophthalmol Vis Sci. 2012 Sep 28;53(10):6668-74
pubmed: 22952119
Korean J Ophthalmol. 2013 Jun;27(3):186-93
pubmed: 23730111
J Curr Ophthalmol. 2016 Aug 27;28(4):199-205
pubmed: 27830204
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421

Auteurs

Francesco Pignatelli (F)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy.

Alfredo Niro (A)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy. alfred.nir@tiscali.it.

Matteo Fallico (M)

Department of Ophthalmology, University of Catania, Catania, Italy.

Fedele Passidomo (F)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy.

Samuele Gigliola (S)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy.

Annalisa Nacucchi (A)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy.

Vincenza Bonfiglio (V)

Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, 90127, Palermo, Italy.

Michele Reibaldi (M)

Department of Surgical Sciences, Eye Clinic Section, University of Turin, Turin, Italy.

Giuseppe Addabbo (G)

Eye Clinic, Hospital "SS. Annunziata", ASL TA, Via F. Bruno, 1, 74010, Taranto, Italy.

Teresio Avitabile (T)

Department of Ophthalmology, University of Catania, Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH